2016 Pharma Dealmaking: Waiting On The High-Value Deals

Six pharma deals announced thus far in 2016 carried up-front values of $1 billion or more, down considerably from the high-volume, high-value M&A industry experienced the prior two years. Pharma manufacturers appear to be recalibrating – digesting previous acquisitions, adjusting to new biotech valuations and taking stock of the political and macro-economic climate – but fundamentals suggest pharma dealmaking will pick up. Pfizer’s $14 billion offer for Medivation might represent a turning point.

IV1608_Feat01_Deals_1200x675

High-value, high-volume pharma M&A was predicted by many in 2016, but the big deals haven’t materialized – yet. While the volume of deals signed so far this year has continued to be robust, the total value has been below what was seen in the two prior years, leaving many to wonder when momentum will pick up, or if it will at all.

The announcement August 22 that Pfizer Inc. beat out several rivals in the auction to buy Medivation Inc....

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Deal-Making

Deals Shaping The Industry, August 2024

 
• By 

<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>

Innovative Drugs: China Gains Deals, But Financing Amounts Drop

 
• By 

China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”

Deal Volume Up, Value Down During The First Half

 
• By 

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals Shaping The Industry, July 2024

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting